Reading the tape
NASDAQ: SEER
Seer, Inc.
Healthcare · Biotechnology
Market Cap
$111.15M
52w High
$2.41
52w Low
$1.65
P/E
-1.54
Volume
185.37K
Outstanding Shares
56.42M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 5.33%Revenue (TTM): 18.17%FCF (TTM): 6.94%P/S: 13th pct
What changed
The stock rose 5.33% over the last year. Revenue grew 18.17% over the trailing twelve months. Operating margin moved from -713.89% to -470.45%. Free cash flow grew 6.94% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -470.45%. A decisive move in revenue — currently up 18.17% — would be the clearest signal to resolve the ambiguity.
Company profile
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome.
CEOOmid C. Farokhzad
SectorHealthcare
IndustryBiotechnology
Employees134
IPO dateDec 4, 2020
Valuation
Forward P/E—
EV/EBITDA-1.23
Enterprise value$81.5M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth6.38%
Gross margin51.06%▲4.24%vs FY2024
Operating margin-470.45%▲34.45%vs FY2024
ROE-28.38%▼7.36%vs FY2024
Analyst consensus
RatingHold
Target price$4.00▲103.05%
1
Buy
2
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 13, 2026
Q2 FY26 · EPS est -$0.28 · Revenue est $3.4M
View